Name: Fluconazole
Brand: Selleck Chemicals
SKU: S1331
Availability: InStock
Rating: 5 (28 reviews)

Jump to

Quality Control

Batch: Purity: 99.94%

99.94

Related Targets	Dehydrogenase HSP Transferase PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase
Other P450 (e.g. CYP17) Inhibitors	Apigenin Baicalein Naringenin Diosmetin Alizarin Sodium Danshensu Naringin Benzbromarone Orteronel Isosilybin

Solubility

In vitro
Batch:

DMSO : 61 mg/mL (199.17 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 61 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	306.27	Formula	C₁₃H₁₂F₂N₆O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	86386-73-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	UK 49858			SMILES	C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	lanosterol 14 alpha-demethylase
In vitro	Fluconazole in combination with amphotericin B (AmB) has a synergistic effect on C. albicans planktonic cells but does not alter AmB activity against biofilms. This compound and caspofungin have an antagonistic effect against biofilms but not with planktonic cells. It-mediated membrane perturbation (due to inhibition of ergosterol biosynthesis) increases calcineurin inhibitor intracellular concentrations. This treatment significantly reduces levels of ergosterol within the cell in C. albicans planktonic cells, leading to cell membrane perturbation. Its activity is less sensitive to acidic medium than is that of ketoconazole. The compound is approximately 16-fold less active than ketoconazole against 35 representative isolates of C. albicans at physiologic pH. Fluvastatin, a cholesterol-lowering drug, exhibits minimal activity (MICs of 64 to >128 mg/mL) against Candida species and Cryptococcus neoformans. This chemical combined with itraconazole exhibits potent activities against C. albicans, C. tropicalis, C. parapsilosis, and C. neoformans, including flucon- azole-resistant strains of C. albicans and C. tropicalis.
In vivo	Fluconazole is very effective in prolonging survival of rats infected with a representative candidal strain. This compound has a dramatic effect on the fungicidal activity of flucytosine in murine cryptococcal meningitis. It combined with flucytosine and amphotericin B have significantly improved activity against cryptococcal meningitis compared with the activity of each drug used alone.
References	[1] https://pubmed.ncbi.nlm.nih.gov/18180354/ [2] https://pubmed.ncbi.nlm.nih.gov/3022641/ [3] https://pubmed.ncbi.nlm.nih.gov/9087504/ [4] https://pubmed.ncbi.nlm.nih.gov/8878602/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-03)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07743593	NOT_YET_RECRUITING	Cryptococcal Antigenemia; HIV-1-infection; Cryptococcal Infection; Cryptococcal Meningitis	University of Minnesota	2027-01-05	PHASE3
NCT04930107	ACTIVE_NOT_RECRUITING	Candidiasis, Vulvovaginal	University of Manitoba	2021-12-07	EARLY_PHASE1
NCT06274554	RECRUITING	Crohn's Disease; Inflammatory Bowel Diseases	Weill Medical College of Cornell University	2024-10-04	PHASE3
NCT05421858	RECRUITING	Candidemia; Candidiasis, Invasive	Basilea Pharmaceutica	2024-12-11	PHASE3
NCT03828773	RECRUITING	Candidiasis; Fungal Infection; Acute Myeloid Leukemia; Genetic Predisposition; Aspergillosis	Bochud Pierre-Yves	2019-02-11
NCT07295314	NOT_YET_RECRUITING	Gut Microbiome; Healthy Adult Male; Antifungal Therapy	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	2026-01	EARLY_PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Fluconazole P450 (e.g. CYP17) inhibitor

Chemical Structure

Molecular Weight: 306.27